Levodopa
Who holds supplier records for Levodopa? 14 organisations hold a current record for Levodopa: an active US FDA Type II Drug Master File or a CEP. A further 4 organisations have only historical (inactive) DMF filings. 11 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: China (6), India (4), Japan (1), United States (1) and 1 other country (1); not recorded for 1.
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Levodopa: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/levodopa
Reading the evidence
- 14 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- 7 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
- US product patents listed
The latest patent listed in the FDA Orange Book for an approved product containing Levodopa expires 21 Oct 2033. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.
Current records (14)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Levodopa. Country is the organisation's recorded country, not necessarily the manufacturing site.
- AJINOMOTO CO INCJapanCEP Company GMP cert on recordActive DMF 12379, 31654 · latest filing Apr 2017
- SHANDONG XINHUA PHARMACEUTICAL CO LTDChinaCEP Company GMP cert on recordActive DMF 22598, 44214 · latest filing Jun 2026
- Divis LaboratoriesIndiaCEP Company GMP cert on recordActive DMF 17874 · latest filing Dec 2004
- MAITHRI DRUGS PRIVATE LTDIndiaCEP Company GMP cert on recordActive DMF 35312 · latest filing Oct 2020
- Zhejiang Huahai Pharmaceutical Co., Ltd.ChinaCEP Company GMP cert on recordActive DMF 31612 · latest filing May 2017
- Zhejiang Wild Wind Pharmaceutical Co.,Ltd.ChinaCEPActive DMF 27938 · latest filing Jan 2014
- ZHEJIANG YONGTAI CHIRAL MEDICINE TECHNOLOGY CO LTDChinaCEPActive DMF 40608 · latest filing Dec 2024
- Acella Pharmaceuticals, LLCUnited StatesActive DMF 32057 · latest filing Jun 2020
- MIANYANG SHENGSHI HEALTH TECHNOLOGY CO LTDActive DMF 42501 · latest filing Sept 2025
- MSN LIFE SCIENCES PRIVATE LIMITEDIndia Company GMP cert on recordActive DMF 43434 · latest filing Jan 2026
- Hetero Drugs LimitedIndiaCEP Company GMP cert on recordInactive DMF 37047 · latest filing Jun 2022
- ChinaCEP
- NetherlandsCEP
- GUANGXI BONGER PHARMACEUTICAL CO., LTD.ChinaCEPValid CEP holder (EDQM); not necessarily the manufacturer
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Valid CEP holder entries (11)
Certificates of Suitability on the EDQM register for Levodopa, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer. 16 certificates in total, including withdrawn, expired, suspended and repeat certificates.
| Holder | Country | Certificate | Issued | EU GMP at holder's address |
|---|---|---|---|---|
| AJINOMOTO CO., INC. Chuo-Ku | JP | CEP 1999-001 - Rev 02 Levodopa | Aug 2026 | — |
| ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. Taizhou | CN | CEP 2017-090 - Rev 05 Levodopa, Micronised I, micronised II and non-micronised | Apr 2026 | Inspected May 2026 Italy |
| ZHEJIANG YONGTAI CHIRAL MEDICINE TECHNOLOGY CO. LTD. Taizhou | CN | CEP 2024-527 - Rev 00 Levodopa | Dec 2025 | — |
| ZHEJIANG WILD WIND PHARMACEUTICAL CO., LTD. Geshan Town | CN | CEP 2021-195 - Rev 01 Levodopa, Enzymatic process | Oct 2025 | — |
| SHANDONG LUKANG PHARMACEUTICAL CO., LTD. Jining City | CN | CEP 2022-202 - Rev 00 Levodopa | Apr 2025 | — |
| TAPI NL B.V. Amsterdam | NL | CEP 1999-187 - Rev 10 Levodopa | Mar 2025 | — |
| HETERO DRUGS LIMITED Hyderabad | IN | R0-CEP 2022-320 - Rev 00 Levodopa | Mar 2023 | — |
| SHANDONG XINHUA PHARMACEUTICAL CO., LTD. Zibo | CN | R1-CEP 2009-174 - Rev 02 Levodopa | Apr 2022 | — |
| MAITHRI DRUGS PRIVATE LIMITED Bonthapally Village | IN | R0-CEP 2020-161 - Rev 00 Levodopa | Mar 2022 | — |
| GUANGXI BONGER PHARMACEUTICAL CO., LTD. Tiandong Town | CN | R1-CEP 2014-348 - Rev 00 Levodopa | Sept 2021 | — |
| DIVI'S LABORATORIES LIMITED Hyderabad | IN | R1-CEP 2005-161 - Rev 04 Levodopa | Jan 2018 | — |
The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.
Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.
Historical records (4)
Organisations whose Type II DMFs for Levodopa are no longer active. These show a past filing, not current supply.
Show all 4 historical records
- India · Inactive DMF 25498 · filed Nov 2011
- Hungary · Inactive DMF 12505 · filed May 1997
- PFC ITALIANA SRL DIV ALFA CHEMICALS ITALIANAInactive DMF 8444 · filed Oct 1989
- LILLY RESEARCH LABORATORIES DIV ELI LILLY AND COInactive DMF 1367 · filed May 1969
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (1 listed product contain Levodopa). The latest listed patent expires 21 Oct 2033. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Overview
Levodopa is a precursor to the neurotransmitter dopamine used to treat Parkinson's disease and dopamine-responsive dystonia. It is often combined with a peripheral decarboxylase inhibitor like carbidopa to increase its effectiveness.
Chemical identity
- IUPAC name
- (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid
- Canonical SMILES
- C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)O
- InChIKey
- WTDRDQBEARUVNC-REOHCLBHSA-N
- Synonyms
- L-DOPA
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Aromatic Amino Acid
- Chemical structure
- Aromatic
Therapeutic areas
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Levodopa?
14 organisations hold an active US FDA Type II Drug Master File or a CEP for Levodopa: AJINOMOTO CO INC (Japan), SHANDONG XINHUA PHARMACEUTICAL CO LTD (China), Divis Laboratories (India), MAITHRI DRUGS PRIVATE LTD (India), Zhejiang Huahai Pharmaceutical Co., Ltd. (China), Zhejiang Wild Wind Pharmaceutical Co.,Ltd. (China), ZHEJIANG YONGTAI CHIRAL MEDICINE TECHNOLOGY CO LTD (China) and Acella Pharmaceuticals, LLC (United States), and 6 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Levodopa Drug Master Files are active?
AJINOMOTO CO INC (DMF 12379, 31654), SHANDONG XINHUA PHARMACEUTICAL CO LTD (DMF 22598, 44214), Divis Laboratories (DMF 17874), MAITHRI DRUGS PRIVATE LTD (DMF 35312), Zhejiang Huahai Pharmaceutical Co., Ltd. (DMF 31612), Zhejiang Wild Wind Pharmaceutical Co.,Ltd. (DMF 27938), ZHEJIANG YONGTAI CHIRAL MEDICINE TECHNOLOGY CO LTD (DMF 40608) and Acella Pharmaceuticals, LLC (DMF 32057) and 2 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
What do the historical Levodopa records mean?
4 organisations have only inactive Type II DMFs for Levodopa. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.
Does Levodopa have a European Certificate of Suitability?
Yes. 11 organisations hold a valid CEP for Levodopa on the EDQM register, including AJINOMOTO CO., INC. Chuo-Ku (JP), ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. Taizhou (CN), ZHEJIANG YONGTAI CHIRAL MEDICINE TECHNOLOGY CO. LTD. Taizhou (CN), ZHEJIANG WILD WIND PHARMACEUTICAL CO., LTD. Geshan Town (CN), SHANDONG LUKANG PHARMACEUTICAL CO., LTD. Jining City (CN) and TAPI NL B.V. Amsterdam (NL) and 5 more. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.
Does the FDA Orange Book list patents for products containing Levodopa?
Yes. The latest patent listed for an approved US product containing Levodopa expires 21 Oct 2033, across 1 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.
How do I qualify a Levodopa supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Levodopa?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.